| Name | Title | Contact Details |
|---|
As part of the Manning Regional Healthcare Center`s comprehensive total health care system, the Hospital has state-of-the-art diagnostic radiology equipment, emergency department care, inpatient medical and surgical treatment and skilled nursing services. All of this and much more allows us to care for the majority of your medical needs right here in Manning.
Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger`s Patient Care segment is the largest owner and operator of O&P patient care clinics with in excess of 730 locations nationwide. Through its Products and Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides therapeutic solutions. Steeped in over 150 years of clinical excellence and innovation, Hanger`s vision is to be the partner of choice for products and services that enhance human physical capability. Hanger helps those with limb loss, paralysis, and other physical challenges become productive members of society after injury or illness. Headquartered in Austin, TX and with locations in 45 states, our employees provide personal independence, increased mobility, and restored functionality.
Lachance Center For Nursing is a Gardner, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carteret Health Care is here for our community, our families and friends — therefore, Carteret is the first word you see. Health Care describes what we do. We call our new graphic icon The Circle of Care. This logo utilizes colors, style and design that evoke images of sun, sand, water, waves, health, care and vitality – everything that makes our community unique. Your community hospital, designed to embrace the future of health care, wrapped in the spirit of the people of Carteret County.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.